HIV-1 antibody-mediated neutralization via a dual-glycan clamp.
- Open access
A novel Fab-dimerized glycan (FDG) antibody with a dual-glycan clamp epitope was isolated, showing approximately 30% breadth against HIV-1 and unique architecture.
- Why it matters: Understanding diverse mechanisms of HIV-1 neutralization is crucial for vaccine design, especially those involving glycan interactions that contribute to viral evasion.
- What they did: Researchers isolated both glycan-reactive and CD4 binding-site antibodies from an HIV-infected donor, using cryo-EM to analyze the FDG antibody's structure and binding mode.
- The result: The FDG antibody's dual-glycan clamp mechanism broadens the scope of neutralizing antibody strategies, offering insights for designing vaccines that target glycan-dependent epitopes.